HUTCHMED

Strong execution on strategic direction, delivering near-term value while charting a path for growth, exemplified by global partnership with Takeda Revenue grew 164% (173% CER) to US$533 million, with net income to HUTCHMED of US$169 million (which�

Vesting of awards under the Long Term Incentive Plan

Annual General Meeting 2024

2023 Annual Report and Notice of Annual General Meeting

HUTCHMED Highlights Data to be Presented at AACR Congress 2024

Monthly Return

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Dissemination of Corporate Communications

HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Grant of Awards under Long Term Incentive Plan and Share Options under Share Option Scheme

Vesting of awards under the Long Term Incentive Plan

Monthly Return

Publication of Form 20-F

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session

HUTCHMED Announces that Inmagene Exercises Option to License Two Drug Candidates as Part of Strategic Partnership

HUTCHMED to Announce 2023 Final Results

Monthly Return

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Monthly Return

Total Voting Rights

Blocklisting Six Monthly Return

Continuing Connected Transactions

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces that it has Completed Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Discloseable Transaction and Connected Transaction in Relation to Disposal of Interest in Consumer Products Businesses

Monthly Return

HUTCHMED Highlights Clinical Data to be Presented at 2023 ESMO Asia and ESMO Immuno-Oncology Congresses

Total Voting Rights

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Monthly Return

Vesting of awards under the Long Term Incentive Plan

HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2023

Monthly Return

Total Voting Rights

HUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Director’s Share Dealing

HUTCHMED Highlights Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

Monthly Return

Total Voting Right

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

Interim Report 2023

Next Day Disclosure Return

Exercise of Share Options by a Director

Monthly Return

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED Receives ELUNATE^® (fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer